Literature DB >> 22217458

Active behaviours produced by antidepressants and opioids in the mouse tail suspension test.

Esther Berrocoso1, Kazutaka Ikeda, Ichiro Sora, George R Uhl, Pilar Sánchez-Blázquez, Juan Antonio Mico.   

Abstract

Most classical preclinical tests to predict antidepressant activity were initially developed to detect compounds that influenced noradrenergic and/or serotonergic activity, in accordance with the monoaminergic hypothesis of depression. However, central opioid systems are also known to influence the pathophysiology of depression. While the tail suspension test (TST) is very sensitive to several types of antidepressant, the traditional form of scoring the TST does not distinguish between different modes of action. The present study was designed to compare the behavioural effects of classical noradrenergic and/or serotonergic antidepressants in the TST with those of opioids. We developed a sampling technique to differentiate between behaviours in the TST, namely, curling, swinging and immobility. Antidepressants that inhibit noradrenaline and/or serotonin re-uptake (imipramine, venlafaxine, duloxetine, desipramine and citalopram) decreased the immobility of mice, increasing their swinging but with no effect on their curling behaviour. No differences were observed between antidepressants that act on noradrenergic or serotoninergic transmission. While opioid compounds also decreased the immobility of the mice [morphine, codeine, levorphanol, (-)-methadone, (±)-tramadol and (+)-tramadol], they selectively increased curling behaviour. Blocking opioid receptors with naloxone prevented the antidepressant-like effect of codeine, and μ-opioid receptor knockout decreased normal curling behaviour and blocked (±)-tramadol-induced curling, further demonstrating the reliability and validity of this approach. These results show that at least two behaviourally distinct processes occur in the TST, highlighting the antidepressant-like effects of opioids evident in this test. Furthermore, our data suggest that swinging and curling behaviours are mediated by enhanced monoamine and opioid neurotransmission, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22217458     DOI: 10.1017/S1461145711001842

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  29 in total

1.  Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Authors:  Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey
Journal:  J Psychopharmacol       Date:  2015-06-04       Impact factor: 4.153

2.  Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients' Perspective.

Authors:  John A Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-29

3.  GAL3 receptor KO mice exhibit an anxiety-like phenotype.

Authors:  Susanne M Brunner; Aitak Farzi; Felix Locker; Barbara S Holub; Meinrad Drexel; Florian Reichmann; Andreas A Lang; Johannes A Mayr; Jorge J Vilches; Xavier Navarro; Roland Lang; Günther Sperk; Peter Holzer; Barbara Kofler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-29       Impact factor: 11.205

Review 4.  Encore: Behavioural animal models of stress, depression and mood disorders.

Authors:  Aleksa Petković; Dipesh Chaudhury
Journal:  Front Behav Neurosci       Date:  2022-08-08       Impact factor: 3.617

5.  An extract of Synedrella nodiflora (L) Gaertn exhibits antidepressant properties through monoaminergic mechanisms.

Authors:  Patrick Amoateng; Kennedy Kwami Edem Kukuia; Jeffrey Amoako Mensah; Dorcas Osei-Safo; Samuel Adjei; Audrey Akyea Eklemet; Emmanuel Atsu Vinyo; Thomas K Karikari
Journal:  Metab Brain Dis       Date:  2018-05-12       Impact factor: 3.584

6.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

Review 7.  Opioid receptors: distinct roles in mood disorders.

Authors:  Pierre-Eric Lutz; Brigitte L Kieffer
Journal:  Trends Neurosci       Date:  2012-12-06       Impact factor: 13.837

8.  The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice.

Authors:  Qian Wang; Yu Long; Ai Hang; Gui-Ying Zan; Xiao-Hong Shu; Yu-Jun Wang; Jing-Gen Liu
Journal:  Psychopharmacology (Berl)       Date:  2016-04-26       Impact factor: 4.530

9.  Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms.

Authors:  Elizabeth A McCarthy; Daniel Dischino; Caroline Maguire; Silvia Leon; Rajae Talbi; Eugene Cheung; Claudio D Schteingart; Pierre J M Rivière; Susan D Reed; Robert A Steiner; Victor M Navarro
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 6.134

10.  EEG and Sleep Effects of Tramadol Suggest Potential Antidepressant Effects with Different Mechanisms of Action.

Authors:  Szabolcs Koncz; Noémi Papp; Noémi Menczelesz; Dóra Pothorszki; György Bagdy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.